Conduct of the Program. (i) The Research Program will be conducted by each Party pursuant to and consistent with the Research Plan.
Conduct of the Program. 1. The Parties shall be responsible jointly for direct transaction of mat ters of Program policy and for the overall coordination of the Program. Each Party shall designate a Program Officer who shall be the principal point of con tact for the other Party in the conduct of the business of the Program.
Conduct of the Program. Forms of cooperation under this Memorandum will be collaborative efforts determined between DOI, USAID, host governments, and stakeholders, geared toward increasing local capacity for improved resource management in selected geographic areas (Program). Activities under this MOU are subject to the availability of personnel, resources, and funds. This Memorandum should not be construed to obligate any particular expenditure or commitment of resources or personnel. The Participants intend, in accordance with Article VI below, to develop specific Annexes in writing before the commencement of each project (Project) hereunder. Each Participant should designate a principal representative, who, as mutually determined by the Participants, should meet to review the activities under this MOU and develop proposals for future activities, as appropriate.
Conduct of the Program. (a) Cubist represents that it has disclosed true and correct copies of its Hiring Profiles for its Sales Force and CSD Force. If Cubist desires to modify any Hiring Profile in a manner that would reduce the minimum qualifications for a position on the Sales Force or CSD Force, Cubist shall notify AstraZeneca in writing of such proposed modification and provide AstraZeneca at least ten (10) business days to comment on such proposed modifications, which comments, if any, shall be considered in good faith by Cubist prior to implementing any such modification.
Conduct of the Program. It shall not be considered a breach of this Agreement by either Party if an objective of the Program is not achieved due to a delay caused by the other Party.
Conduct of the Program. Each party shall conduct its obligations under the Program in good scientific manner and in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices, to attempt to achieve its objectives efficiently and expeditiously. Each party shall allocate sufficient time, effort, equipment, facilities and personnel with sufficient skills and experience to the Program to conduct its obligations under the Program and to accomplish the objectives thereof.
Conduct of the Program. The Program shall be performed by Virpax in the Territory. Under the direction and supervision of the JRC, Virpax shall (a) perform or cause to be performed its obligations under the Program in good scientific manner and in compliance in all material respects with all Applicable Law, including good laboratory practices and good clinical practices, and (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. Following the Effective Date, Virpax shall promptly commence the Program, provided, however, that Virpax shall not be obligated to initiate any activities under the Clinical Development Plan until the Funding has been fully received by Virpax or Virpax has notified Nanomerics in accordance with section 13.5.1.1 that it has secured equal or greater funding from a Third Party source which is available and intended for the Program.
Conduct of the Program. During the Collaboration Term and under the direction and supervision of the JRC, each Party shall (a) perform or cause to be performed its obligations under the Program in good scientific manner and in compliance in all material respects with all Applicable Law, including good laboratory practices and good clinical practices, and (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. Following the Effective Date, the Parties shall promptly commence the Program, provided, however, that neither party shall be obligated to initiate any activities under the Clinical Development Plan until the Funding has been fully received by Virpax. Each Party shall assume responsibility for its own costs and expenses for the Program or as otherwise might be agreed in writing.
Conduct of the Program. The Program shall be performed by Virpax in the Territory. Under the direction and supervision of the JRC, Virpax shall (a) perform or cause to be performed its obligations under the Program in good scientific manner and in compliance in all material respects with all Applicable Law, including good laboratory practices and good clinical practices, and (b) allocate sufficient time, effort, equipment and skilled personnel to complete such activities successfully and promptly. Following the New Effective Date, Virpax shall promptly commence the Program.
Conduct of the Program
